Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis
- H. Gali-Muhtasib, R. Hmadi, Mike Kareh, Rita Tohmé, N. Darwiche
- Biology, Medicine
- 11 September 2015
Despite remarkable progress in the discovery and development of novel cancer therapeutics, cancer remains the second leading cause of death in the world. For many years, compounds derived from plants… Expand
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
- J. Sangodkar, Abbey L Perl, +42 authors G. Narla
- The Journal of clinical investigation
- 1 June 2017
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the… Expand
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired… Expand
Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.
- J. Ngeow, Y. Ni, Rita Tohmé, Fu Song Chen, G. Bebek, C. Eng
- The Journal of clinical endocrinology and…
- 8 April 2014
CONTEXT RASAL1 has recently been identified as an important tumor suppressor for sporadic thyroid tumorigenesis, particularly for follicular thyroid cancer (FTC) and anaplastic thyroid cancer.… Expand
Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid malignancies, require investigation and countermeasures. Both are nucleoside analog pro-drugs processed by… Expand
Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy
Acute myeloid leukemia (AML) is one of the most prevalent and aggressive forms of leukemia. Currently utilized therapeutic agents do not achieve long-term survival for the majority of patients with… Expand
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies
We have created the immunodeficient SRG rat, a Sprague-Dawley Rag2/Il2rg double knockout that lacks mature B cells, T cells, and circulating NK cells. This model has been tested and validated for use… Expand
A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA).
- D. Sohal, S. Krishnamurthi, Rita Tohmé, D. Shepard, A. Khorana, Y. Saunthararajah
- 1 February 2020
699Background: PDA treatment is limited to cytotoxic drugs. A key factor limiting their efficacy is TP53 mutations, omnipresent in PDA, which counter apoptosis-mediated cell kill. We evaluated a no...
Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer
PP2A is a phosphatase tumor suppressor that is dysregulated and deactivated in lung cancer. It is one of the most abundant cellular proteins and regulates the activity of numerous kinases Where… Expand
Abstract 1827: Direct activation of the tumor suppressor protein phosphatase 2A as a therapeutic strategy for TKI-resistant lung adenocarcinoma
Most lung adenocarcinoma (LUAD) patients develop acquired resistance to tyrosine kinase inhibitors (TKI) via mechanisms enabling the sustained activation of the MAPK and PI3K oncogenic pathways… Expand